Researchers testing a novel HIV treatment approach report that a single infusion may suppress the virus for years, according to findings to be presented this week. The therapy relies on genetically modified immune cells, a technique already proven effective against certain blood cancers.
The study involved a small patient group, but results suggest the approach could transform HIV management. Scientists engineer patients' T cells, a type of white blood cell, to recognize and attack HIV-infected cells. After receiving the modified cells through a single infusion, patients in the trial showed sustained viral suppression without traditional antiretroviral medications.
This advancement builds on CAR-T cell therapy, which has successfully treated acute lymphoblastic leukemia and other blood malignancies. Researchers adapted this cancer treatment strategy specifically for HIV, modifying T cells to target proteins on the surface of infected cells.
The benefit of long-acting suppression from a single treatment addresses a persistent challenge in HIV care: medication adherence. Many patients struggle with daily pill regimens or frequent infusions required by current antiretroviral therapies. A durable single infusion could simplify treatment dramatically.
The current study remains preliminary, involving only a handful of participants. Larger trials must confirm whether the viral suppression persists over longer periods and whether the approach works consistently across diverse patient populations. Researchers also need to assess potential side effects and determine which patients might benefit most.
The findings align with the broader push toward cure-focused strategies rather than lifelong management. Similar cellular therapies are being explored by multiple research groups, reflecting growing confidence in this direction.
HIV treatment has progressed remarkably since the 1990s, with modern antiretroviral combinations reducing viral loads to undetectable levels in most patients who access medication. This emerging cellular therapy represents another option, particularly valuable for people who struggle with conventional treatment adherence or who seek alternatives to daily medications.
Results presented this week may